Suffolk Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Suffolk Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-37,827	Closed	-$484K	–	135
2018 Q2	$484K	Buy	37,827 +6,456	+21%	+$94.4K	0.07%	112
2018 Q1	$530K	Buy	+31,371	New	+$475K	0.08%	118
2017 Q4	–	Sell	-57,188	Closed	-$443K	–	137
2017 Q3	$443K	Buy	+57,188	New	+$362K	0.06%	114

Other funds holding IOVA

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Suffolk Capital Management's IOVA Position: Q3 2018 in Review

Suffolk Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2018, closing a stake of 37,827 shares — an estimated $484K sold.

Suffolk Capital Management first reported a position in IOVA in Q3 2017 and held it in 3 quarters. The position peaked at $530K in Q1 2018. 131 funds tracked by Wall St. Rank hold IOVA as of Q3 2018.

Suffolk Capital Management reported no remaining Iovance Biotherapeutics position as of Q3 2018 after selling out during the quarter.
Suffolk Capital Management sold 37,827 Iovance Biotherapeutics shares in Q3 2018, an estimated $484K.
Suffolk Capital Management first reported a position in Iovance Biotherapeutics in Q3 2017 and held it in 3 quarters.
Suffolk Capital Management's Iovance Biotherapeutics position peaked at $530K in Q1 2018.
131 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2018.

Based on Suffolk Capital Management's 13F filing for Q3 2018, filed 9 Nov 2018.